Laboratorios Farmaceuticos ROVI (ROVI) - Total Assets

Latest as of September 2025: €922.07 Million EUR ≈ $1.08 Billion USD

Based on the latest financial reports, Laboratorios Farmaceuticos ROVI (ROVI) holds total assets worth €922.07 Million EUR (≈ $1.08 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Laboratorios Farmaceuticos ROVI - Total Assets Trend (2003–2024)

This chart illustrates how Laboratorios Farmaceuticos ROVI's total assets have evolved over time, based on quarterly financial data. Also see how much is Laboratorios Farmaceuticos ROVI worth for the company's overall valuation and market capitalisation.

Laboratorios Farmaceuticos ROVI - Asset Composition Analysis

Current Asset Composition (December 2024)

Laboratorios Farmaceuticos ROVI's total assets of €922.07 Million consist of 59.1% current assets and 40.9% non-current assets. Review ROVI current and long-term liabilities to assess the company's total debt and financial obligations.

Asset Category	Amount (EUR)	% of Total Assets
Cash & Equivalents	€0.00	3.3%
Accounts Receivable	€129.50 Million	15.6%
Inventory	€329.95 Million	39.7%
Property, Plant & Equipment	€0.00	0.0%
Intangible Assets	€33.95 Million	4.1%
Goodwill	€0.00	0.0%

Asset Composition Trend (2003–2024)

This chart illustrates how Laboratorios Farmaceuticos ROVI's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ROVI share price today for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Laboratorios Farmaceuticos ROVI's current assets represent 59.1% of total assets in 2024, an increase from 0.0% in 2003.
Cash Position: Cash and equivalents constituted 3.3% of total assets in 2024, up from 0.0% in 2003.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 2.0% in 2003.
Asset Diversification: The largest asset category is inventory at 39.7% of total assets.

Laboratorios Farmaceuticos ROVI Competitors by Total Assets

Key competitors of Laboratorios Farmaceuticos ROVI based on total assets are shown below.

Company	Country	Total Assets
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Germany	€1.60 Trillion
GALDERMA GROUP AG NYSE:GALDY	USA	$13.39 Billion
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	USA	$15.42 Trillion
Beijing Tongrentang Co Ltd SHG:600085	China	CN¥31.82 Billion
Takeda Pharmaceutical Company Limited F:TKDA	Germany	€15.41 Trillion
Changchun High & New Technology Industries Group Inc SHE:000661	China	CN¥30.77 Billion
Neuland Laboratories Limited NSE:NEULANDLAB	India	Rs29.30 Billion
China Resources Double-Crane Pharmaceutical Co Ltd SHG:600062	China	CN¥17.01 Billion

Laboratorios Farmaceuticos ROVI - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	3.02	2.50	2.97
Quick Ratio	1.32	0.94	1.12
Cash Ratio	0.00	0.00	0.00
Working Capital	€373.77 Million	€332.34 Million	€241.69 Million

Laboratorios Farmaceuticos ROVI - Advanced Valuation Insights

This section examines the relationship between Laboratorios Farmaceuticos ROVI's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	5.99
Latest Market Cap to Assets Ratio	4.16
Asset Growth Rate (YoY)	4.0%
Total Assets	€832.02 Million
Market Capitalization	$3.46 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values Laboratorios Farmaceuticos ROVI's assets at a significant premium (4.16x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: Laboratorios Farmaceuticos ROVI's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Laboratorios Farmaceuticos ROVI (2003–2024)

The table below shows the annual total assets of Laboratorios Farmaceuticos ROVI from 2003 to 2024.

Year	Total Assets	Change
2024-12-31	€832.02 Million ≈ $972.72 Million	+4.02%
2023-12-31	€799.88 Million ≈ $935.15 Million	-8.97%
2022-12-31	€878.70 Million ≈ $1.03 Billion	+19.93%
2021-12-31	€732.68 Million ≈ $856.58 Million	+27.55%
2020-12-31	€574.44 Million ≈ $671.58 Million	+12.37%
2019-12-31	€511.21 Million ≈ $597.66 Million	+26.95%
2018-12-31	€402.70 Million ≈ $470.80 Million	+34.96%
2017-12-31	€298.38 Million ≈ $348.84 Million	+3.66%
2016-12-31	€287.85 Million ≈ $336.52 Million	+9.10%
2015-12-31	€263.85 Million ≈ $308.46 Million	+0.97%
2014-12-31	€261.32 Million ≈ $305.51 Million	+10.76%
2013-12-31	€235.92 Million ≈ $275.82 Million	+6.10%
2012-12-31	€222.36 Million ≈ $259.97 Million	-2.50%
2011-12-31	€228.07 Million ≈ $266.64 Million	+7.13%
2010-12-31	€212.89 Million ≈ $248.89 Million	+28.31%
2009-12-31	€165.91 Million ≈ $193.97 Million	+37.63%
2008-12-31	€120.55 Million ≈ $140.93 Million	+7.48%
2007-12-31	€112.16 Million ≈ $131.13 Million	+47.50%
2006-12-31	€76.04 Million ≈ $88.90 Million	-100.00%
2005-12-31	€8.15 Trillion ≈ $9.53 Trillion	+103335.75%
2004-12-31	€7.88 Billion ≈ $9.21 Billion	+16113.55%
2003-12-31	€48.60 Million ≈ $56.82 Million	--

About Laboratorios Farmaceuticos ROVI

MC:ROVI Spain Drug Manufacturers - Specialty & Generic

Market Cap

$3.46 Billion

€2.96 Billion EUR

Market Cap Rank

#4500 Global

#38 in Spain

Share Price

€57.85

Change (1 day)

+0.96%

52-Week Range

€53.65 - €85.55

All Time High

€90.54